MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
Mylan Pharmaceuticals
Drug class
PAH Agents- Endothelin Receptor Antagonists
PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1). Read more about PAH Agents- Endothelin Receptor Antagonists
35 drugs in this class 26 manufacturers
Drugs in PAH Agents- Endothelin Receptor Antagonists
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
TEVA PHARM
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
ALEMBIC PHARMAC
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
APOTEX CORP
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
ALEMBIC PHARMAC
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
SANDOZ
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
LAURUS LABS LIM
MACITENTAN
PAH AGENTS- ENDOTHELIN RECEPTOR ANTAGONISTS · PULMONARY ARTERIAL HYPERTENSION
ANI PHARMACEUTI
Filter & compare in the drug finder →
Opens the drug finder with PAH Agents- Endothelin Receptor Antagonists preselected. Add indication or manufacturer filters there.
PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1).
These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells.
By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression.
-
fda.gov
PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1)
-
fda.gov
PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1)
-
ctdssmap.com
PAH agents that are endothelin receptor antagonists comprise a therapeutic drug class indicated for the management of pulmonary arterial hypertension (WHO Group 1) These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells
-
ajmc.com
These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells
-
nih.gov
These agents—including ambrisentan, bosentan, and macitentan—function by competitively binding to and blocking endothelin receptors (ETA and/or ETB) on vascular smooth muscle cells By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression
-
fda.gov
By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression
-
fda.gov
By impeding the actions of endothelin-1, a potent endogenous vasoconstrictor and smooth muscle mitogen, they induce pulmonary vasodilation, attenuate abnormal vascular remodeling, improve exercise capacity, and reduce the risk of clinical disease progression
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.